Kurkjian C, Patel S, Kamble R, Dunn ST, Kern W, Kharfan-Dabaja MA. Acute promyelocytic leukemia and constitutional trisomy 21. Cancer Genet Cytogenet. 2006 Mar; 165(2):176-9.Kurkjian C, Patel S, Kamble R, et al. Acute promyelocytic leukemia and constitutional trisomy 21. Cancer Genet ...
They could not have suspected brain and/or leptomeningeal metastases that were symptomatic, untreated, or needed therapy, nor could they have acute promyelocytic leukemia. Study participants were given oral EP0042 at doses ranging from 20 mg to 50 mg. The primary outcome measure of the research ...
Clinical man- agement of primary non-acute promyelocytic leukemia acute myeloid leukemia: Practice guidelines by the Italian Society of Hematology, the Italian Society of Experimental Hematology, and the Italian Group for Bone Marrow Transplanta- tion. Haematologica 2009; 94: 102–112. 6 Ferrrara ...
Clinical management of primary non-acute promyelocytic leukemia acute myeloid leukemia: Practice guidelines by the Italian Society of Hematology, the Italian Society of Experimental Hematology, and the Italian Group for Bone Marrow Transplantation. Haematologica 2009; 94: 102–112. Article Google Scholar ...
Acute myeloid leukemia (AML) is most common in the elderly, and most elderly are thought to be unfit for intensive treatment because of the risk of fatal toxicity. The Swedish Acute Leukemia Registry covers 98% of all patients with AML (nonacute promyelocytic leukemia) diagnosed in 1997 to 20...
(2011). Prognosis and therapy when acute promyelocytic leukemia and other ``good risk'' acute myeloid leukemias occur as a therapy-related myeloid neoplasm. Mediterr J Hematol Infect Dis 3, e2011032.Larson RA, Le Beau MM. Prognosis and therapy when acute promyelocytic leukemia and other "good...
Acute promyelocytic leukemiaRetinoic acid receptor-αPML/RARαAll-transretinoic acidWnt/β-catenin pathwayAXLReceptor tyrosine kinaseBackground Acute promyelocytic leukemia (APL) is a subset of acute myeloid leukemia (AML) which is characterized by the fusion of promyelocytic leukemia PML and retinoic ...
acute promyelocytic leukemia; target therapy; genetic heterogeneity1. Introduction Heterogeneity in the universe of leukemias is a constant reality. When it comes to acute leukemias, APL is quite distinct because it has a pathognomonic marker, i.e., the translocation between chromosomes 15 and 17,...
genes, such as the CBF group mutations, which primarily manifest as translocations detectable by fluorescence in situ hybridization (FISH), such as t(8;21), inv(16), and t(15;17), the latter being responsible for the PML-RAR-α gene fusion characteristic of acute promyelocytic leukemia (...